Hypothesis: Restoring indole‑3‑propionic acid (IPA) activation of the Aryl Hydrocarbon Receptor (AhR) in hematopoietic stem and progenitor cells (HSPCs) reduces DNA damage‑induced senescence of immune cells, thereby diminishing senescent‑associated secretory phenotype (SASP) spread to peripheral tissues and slowing systemic aging.

Mechanistic rationale: IPA, a tryptophan metabolite produced by Clostridium sporogenes, is a high‑affinity AhR ligand that promotes Treg/Th17 balance and intestinal barrier integrity [2]. In HSPCs, AhR activation triggers a transcriptional program that upregulates Nrf2‑mediated antioxidant responses and enhances base excision repair (BER) through increased expression of Ogg1 and MUTYH. Improved DNA repair lowers the burden of oxidative lesions that drive p16^INK4a^ and p21^CIP1^ senescence in myeloid and lymphoid lineages. Consequently, senescent immune cells produce less IL‑6, TNF‑α, and MMPs, reducing paracrine senescence induction in kidney, liver, and lung. This breaks the positive feedback loop where gut dysbiosis depletes IPA, immune senescence worsens permeability, and further IPA loss ensues.

Testable predictions:

1. In Ercc1‑deficient mice (immune‑specific DNA repair loss) [1], chronic IPA supplementation (via diet or gavage) will increase AhR nuclear translocation in Lin^−Sca1^+cKit^+ HSPCs, elevate Nrf2 target genes (Ho‑1, Nqo1), and reduce γH2AX foci compared with vehicle controls.
2. Treated mice will show decreased frequencies of p16^+ p21^+ CD4^+ T cells and CD11b^+ Gr‑1^+ myeloid cells in blood and spleen, accompanied by lower circulating SASP cytokines (IL‑6, IL‑1β).
3. Histological analysis of kidney, liver, and lung will reveal reduced senescence-associated β‑galactosidase activity and collagen deposition.
4. Functional immune assays (phagocytosis, T‑cell proliferative response to anti‑CD3/CD28) will be improved relative to untreated Ercc1^−/− controls.
5. Transplanting HSPCs from IPA‑treated Ercc1^−/− donors into young wild‑type recipients will confer resistance to senescence induction, whereas transplanting untreated HSPCs will transmit the senescence phenotype.

Falsifiability: If IPA supplementation fails to AhR‑dependent Nrf2 activation in HSPCs, does not reduce immune‑cell senescence markers, or does not attenuate organ‑level senescence and inflammation, the hypothesis is refuted. Conversely, a positive outcome supports the notion that targeting the IPA‑AhR axis in hematopoietic cells can reprogram immune surveillance to delay aging.

Experimental approach: Use Ercc1^−/− mice with Vav‑Cre‑driven hematopoietic Ercc1 deletion. Administer IPA (10 mg/kg/day) in drinking water for 12 weeks. Controls receive vehicle. Measure AhR signaling (CYP1A1 expression), DNA repair (COMET assay, Ogg1/MYH activity), senescence (flow cytometry for p16/p21, SA‑β‑gal), SASP (Luminex cytokine panel), tissue pathology (hydroxyproline, histology), and immune function. Include AhR antagonist (CH‑223191) and Nrf2 knockout groups to dissect pathway specificity.

This hypothesis extends the observed immune‑centric aging model by proposing a concrete microbial metabolite‑driven repair mechanism within HSPCs, offering a direct, testable intervention point that could disrupt the immune‑mediated propagation of systemic aging.